Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients
Accuray Incorporated (NASDAQ: ARAY) announced a study in Frontiers in Oncology indicating that its CyberKnife robotic radiotherapy platform significantly improves survival rates for early-stage breast cancer patients receiving accelerated partial breast irradiation (APBI). The study suggests that CyberKnife's delivery of APBI could reduce the risk of secondary lung cancers and improve patient outcomes compared to traditional techniques. Utilizing advanced technology, CyberKnife offers precise radiation delivery, enhancing treatment efficacy while minimizing damage to surrounding tissues.
- The study shows CyberKnife APBI could improve survival rates in early-stage breast cancer patients.
- Potential reduction in secondary lung cancer risk by over 85% due to the precision of CyberKnife technology.
- CyberKnife is the first robotic radiotherapy platform providing ultra-hypofractionated APBI, enhancing patient experience.
- None.
SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife® robotic radiotherapy platform. Study investigators performed complex modeling that also indicates the survival rate could be better with CyberKnife APBI than other radiation delivery approaches including volumetric-modulated arc therapy, three-dimensional conformal radiation therapy ABPI and high dose rate brachytherapy.
Early-stage breast cancer treatment typically includes breast-conserving surgery followed by radiotherapy. The addition of radiotherapy can extend survival that may be offset by the development of a secondary cancer – like lung tumors – many years following treatment. Radiotherapy technology that has the ability to precisely deliver the prescribed radiation dose only to the target while minimizing dose to the surrounding healthy tissue is essential to reduce the incidence of secondary cancers.
"Important findings from this study of dynamic modeling using Real World Evidence (RWE) underscore the fact that we potentially can help to prevent unnecessary deaths related to radiation-induced secondary lung cancer associated with the treatment of early-stage breast cancer. Advanced radiotherapy techniques can decrease the dose to the lung delivered during breast cancer treatment with a probable reduction in risk of mortality," said Frank A. Vicini, M.D., FACR, FASTRO, FABS, chief academic officer for Michigan Healthcare Professionals and national principal investigator at GenesisCare Oncology. "Our study shows that APBI delivered in 1-5 sessions, called ultra-hypofractionated APBI, using 4π robotic technology provides the most effective option with a potential reduction in the risk of mortality of over
The CyberKnife platform, the first and only robotic radiotherapy platform, features a compact linear accelerator mounted on a highly maneuverable robotic arm that moves around the resting patient while delivering non-coplanar radiation beams from potentially thousands of unique angles, targeting only the tumor while minimizing radiation dose to healthy tissue. The CyberKnife platform is equipped with artificial intelligence (AI)-driven motion synchronization technology, Synchrony®, that adjusts the radiation beam to the patient or tumor movement, allowing the patient to breathe freely while keeping precisely on target throughout the treatment, automatically. Together, the CyberKnife robotic design with Synchrony facilitates the delivery of ultra-hypofractionated APBI with extreme accuracy and precision, reducing patient burden.
"Accuray is leading the transformation of radiotherapy by partnering with our customers to develop technology and therapies that make a real difference in patients' lives. This study reinforces the unparalleled accuracy of a 4π-like robotic CyberKnife platform and shows its tremendous potential as a treatment for early-stage breast cancer," said Suzanne Winter, president at Accuray. "Secondary lung cancers most frequently occur two to three decades after radiation treatment for early-stage breast cancer, a significant issue for people with long life expectancies. The CyberKnife platform's ability to deliver radiotherapy with sub-millimeter accuracy and precision is critical to the continuing health and well-being of these patients."
About the Study
The purpose of the study was to determine the risk of developing radiation-induced secondary lung cancer (SLC) in patients diagnosed with early-stage breast cancer and whether different radiotherapy techniques could save lives. An analysis of the SEER database, the Surveillance, Epidemiology, and End Results Program, from 1988 to 2012 identified 765,697 non-metastatic breast cancers of which
About SEER
The SEER Program provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS).
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the ability of the CyberKnife platform to improve survival in early-stage breast cancer patients, the CyberKnife platform's potential for the treatment of early-stage breast cancer, clinical applications, clinical results, patient experiences and outcomes, and Accuray Incorporated's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product offerings and improvements; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products, including product improvements, for certain users and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 17, 2021, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contacts: | |
Beth Kaplan | Christy Maginn |
Public Relations Director, Accuray | Havas |
+1 (408) 789-4426 | +1 (703) 297-7194 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-cyberknife-robotic-radiotherapy-platform-could-significantly-improve-survival-in-early-stage-breast-cancer-patients-301407113.html
SOURCE Accuray Incorporated
FAQ
What did the recent Accuray study published in Frontiers in Oncology find?
How does Accuray's CyberKnife compare to other radiotherapy techniques?
What are the potential benefits of using CyberKnife for breast cancer treatment according to the study?
When was the Accuray study released?
What is the stock symbol for Accuray?
